EG-70 for Bladder Cancer
This trial is testing a new treatment for patients with NMIBC who have failed BCG therapy or who are BCG-naïve. The trial has two phases: a dose-escalation phase to establish safety and a Phase 2 efficacy study. Eligible patients will be enrolled in either Phase 1 or Phase 2.
- Superficial Bladder Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Can people with the relevant medical condition participate in this trial now?
"Yes, this clinical trial is still recruiting patients. The most recent update on the progress of the trial was posted on 5/11/2022, and recruitment began on 4/22/2021."
How many people can potentially enroll in this research project?
"That is accurate. The clinical trial, which was first announced on April 22nd 2021, is still recruiting patients as of May 11th 2022. They are looking for a total of 222 people to participate at 8 different locations."
What are the primary goals of this clinical trial?
"The primary goal of this study, which will last approximately 48 weeks, is to Phase 1: Nature, incidence, relatedness, and severity of all AEs and SAEs according to the CTCAE v5.0.. Additionally, researchers are looking at secondary outcomes including Phase 2: Progression-free survival (PFS), Phase 1: The number of patients who experience a DLT through the end of Cycle 1 , andPhase 2: Duration of response of the responding patients."
Are there different research hospitals participating in this clinical trial across Canada?
"In addition to Laura & Isaac Perlmutter Cancer Center at NYU Langone Health in New York, this trial is also running out of New Jersey Urology, LLC in Voorhees and UT Southwestern Medical Center in Dallas. There are a total of 8 different locations for this study."